Details of the Drug

General Information of Drug (ID: DM5SYZP)

• Drug Name: Disopyramide
• Synonyms: Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide

Indication

Disease Entry	ICD 11	Status	REF
Long QT syndrome	BC65.0	Approved	[1]
Ventricular arrhythmias	BC71	Approved	[2]
Urinary incontinence	MF50.2	Withdrawn from market	[2]

• Therapeutic Class: Antiarrhythmic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 339.5
  Logarithm of the Partition Coefficient (xlogp); 3.2
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
  Bioavailability: The bioavailability of drug is 100% []
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.9 mL/min/kg [4]
  Elimination: 55% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6.7 (range 4 - 10) hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.89136 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.16% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.52 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Poisoning and toxicity	Not Available	CYP2D6	OTZJC802	[6]
Sudden cardiac death	Not Available	SCN5A	OTGYZWR6	[6]
Sudden cardiac death	Not Available	KCNQ1	OT8SPJNX	[6]

• Chemical Identifiers:
  Formula: C21H29N3O
  IUPAC Name: 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
  Canonical SMILES: CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
  InChI: InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
  InChIKey: UVTNFZQICZKOEM-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3114
  ChEBI ID: CHEBI:4657
  CAS Number: 3737-09-5
  DrugBank ID: DB00280
  TTD ID: D0M4YC
  VARIDT ID: DR00644
  INTEDE ID: DR0518
  ACDINA ID: D00205
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Blocker	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[10]
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[11]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[6]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Gene/Protein Processing	[10]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[13]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[14]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1)	OT8SPJNX	KCNQ1_HUMAN	Drug Response	[6]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Drug Response	[6]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Gene/Protein Processing	[12]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Disopyramide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Bretylium	DM1FX74	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Bretylium.	Ventricular tachyarrhythmia [BC71]	[15]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[16]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[17]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[16]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[18]

Coadministration of a Drug Treating the Disease Different from Disopyramide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Disopyramide when combined with Bethanechol.	Abnormal micturition [MF50]	[19]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Repaglinide.	Acute diabete complication [5A2Y]	[20]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Glibenclamide.	Acute diabete complication [5A2Y]	[20]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Tolazamide.	Acute diabete complication [5A2Y]	[20]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Nateglinide.	Acute diabete complication [5A2Y]	[20]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-glulisine.	Acute diabete complication [5A2Y]	[20]
Acetohexamide	DMR6N7H	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Acetohexamide.	Acute diabete complication [5A2Y]	[20]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-aspart.	Acute diabete complication [5A2Y]	[21]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Glipizide.	Acute diabete complication [5A2Y]	[20]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[16]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Midostaurin.	Acute myeloid leukaemia [2A60]	[16]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Idarubicin.	Acute myeloid leukaemia [2A60]	[16]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[16]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Arn-509.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Oliceridine.	Acute pain [MG31]	[16]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Disopyramide due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[22]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Scopolamine.	Addictive disorder [6C50-6C5Z]	[23]
Terfenadine	DM4KLPT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Disopyramide when combined with Tacrine.	Alzheimer disease [8A20]	[25]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Memantine.	Alzheimer disease [8A20]	[23]
Galantamine	DMEO794	Moderate	Antagonize the effect of Disopyramide when combined with Galantamine.	Alzheimer disease [8A20]	[25]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Disopyramide when combined with Rivastigmine.	Alzheimer disease [8A20]	[25]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Disopyramide when combined with Donepezil.	Alzheimer disease [8A20]	[25]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Disopyramide and Metronidazole.	Amoebiasis [1A36]	[15]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Disopyramide due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[22]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Ivabradine.	Angina pectoris [BA40]	[22]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Bepridil.	Angina pectoris [BA40]	[26]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Dronedarone.	Angina pectoris [BA40]	[16]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Disopyramide caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[27]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[16]
Promazine	DMZAL7W	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Promazine.	Appearance/behaviour symptom [MB23]	[16]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Cilostazol.	Arterial occlusive disease [BD40]	[16]
Voriconazole	DMAOL2S	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Voriconazole.	Aspergillosis [1F20]	[16]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Disopyramide caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[28]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Levalbuterol.	Asthma [CA23]	[29]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Terbutaline.	Asthma [CA23]	[30]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Pirbuterol.	Asthma [CA23]	[30]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Salbutamol.	Asthma [CA23]	[31]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Formoterol.	Asthma [CA23]	[30]
Atomoxetine	DM5L6HI	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Atomoxetine.	Attention deficit hyperactivity disorder [6A05]	[16]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[16]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[16]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Ciprofloxacin XR	DM2NLS9	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[32]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Disopyramide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[33]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[15]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Disopyramide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[16]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Capreomycin	DMNZBRY	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Capreomycin.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Troleandomycin	DMUZNIG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Troleandomycin.	Bacterial infection [1A00-1C4Z]	[15]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[32]
Telithromycin	DMZ4P3A	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[34]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Retigabine.	Behcet disease [4A62]	[16]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Cariprazine.	Bipolar disorder [6A60]	[23]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Disopyramide and Loperamide.	Bowel habit change [ME05]	[35]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lapatinib.	Breast cancer [2C60-2C6Y]	[16]
Tucatinib	DMBESUA	Major	Decreased metabolism of Disopyramide caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Tamoxifen	DMLB0EZ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[16]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Toremifene.	Breast cancer [2C60-2C6Y]	[16]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Bosutinib.	Breast cancer [2C60-2C6Y]	[16]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Grepafloxacin.	Bronchitis [CA20]	[36]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sotalol.	Cardiac arrhythmia [BC9Z]	[16]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Disopyramide when combined with Acetylcholine.	Cataract [9B10]	[37]
Iodipamide	DMXIQYS	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Iodipamide.	Cholelithiasis [DC11]	[38]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Disopyramide caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[39]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Disopyramide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[16]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[40]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[40]
Ipratropium	DMFQ320	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Ipratropium.	Chronic obstructive pulmonary disease [CA22]	[40]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[40]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[30]
Oxaliplatin	DMQNWRD	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Oxaliplatin.	Colorectal cancer [2B91]	[16]
Panitumumab	DMQPD1F	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Panitumumab.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Isoproterenol.	Conduction disorder [BC63]	[30]
Methohexital	DM7YMIT	Moderate	Increased metabolism of Disopyramide caused by Methohexital mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[39]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Halothane.	Corneal disease [9A76-9A78]	[16]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Propofol.	Corneal disease [9A76-9A78]	[41]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sevoflurane.	Corneal disease [9A76-9A78]	[16]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Disopyramide caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[39]
Lidocaine	DML4ZOT	Moderate	Increased risk of cardiac depression by the combination of Disopyramide and Lidocaine.	Corneal disease [9A76-9A78]	[42]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Probucol.	Coronary atherosclerosis [BA80]	[16]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Methadone.	Cough [MD12]	[16]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Clofazimine.	Crohn disease [DD70]	[16]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Mifepristone.	Cushing syndrome [5A70]	[16]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pasireotide.	Cushing syndrome [5A70]	[16]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Osilodrostat.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Disopyramide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[43]
Ethanol	DMDRQZU	Minor	Increased renal excretion of Disopyramide caused by Ethanol.	Cystitis [GC00]	[44]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Disopyramide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[45]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Disopyramide caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[46]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sertraline.	Depression [6A70-6A7Z]	[16]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Trimipramine.	Depression [6A70-6A7Z]	[16]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Cyclobenzaprine.	Depression [6A70-6A7Z]	[23]
Imipramine	DM2NUH3	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Imipramine.	Depression [6A70-6A7Z]	[16]
Fluoxetine	DM3PD2C	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Fluoxetine.	Depression [6A70-6A7Z]	[16]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Nortriptyline.	Depression [6A70-6A7Z]	[16]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Disopyramide caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[28]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Escitalopram.	Depression [6A70-6A7Z]	[16]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Disopyramide and OPC-34712.	Depression [6A70-6A7Z]	[23]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Clomipramine.	Depression [6A70-6A7Z]	[16]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Trazodone.	Depression [6A70-6A7Z]	[16]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Amoxapine.	Depression [6A70-6A7Z]	[16]
Mirtazapine	DML53ZJ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Mirtazapine.	Depression [6A70-6A7Z]	[16]
Protriptyline	DMNHTZI	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Protriptyline.	Depression [6A70-6A7Z]	[16]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Doxepin.	Depression [6A70-6A7Z]	[16]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Maprotiline.	Depression [6A70-6A7Z]	[16]
Venlafaxine	DMR6QH0	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Venlafaxine.	Depression [6A70-6A7Z]	[16]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Hyoscyamine.	Digestive system disease [DE2Z]	[23]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Mepenzolate.	Digestive system disease [DE2Z]	[23]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Oxybutynine.	Discovery agent [N.A.]	[23]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[16]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Meclizine.	Dizziness and giddiness [MB48]	[23]
Trihexyphenidyl	DMB19L8	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Trihexyphenidyl.	Dystonic disorder [8A02]	[23]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Deutetrabenazine.	Dystonic disorder [8A02]	[16]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ingrezza.	Dystonic disorder [8A02]	[16]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Disopyramide and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[47]
Primidone	DM0WX6I	Moderate	Increased metabolism of Disopyramide caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Disopyramide caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Disopyramide caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Disopyramide caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Disopyramide caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Disopyramide caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Timolol	DM3NXRU	Major	Additive hypotensive effects by the combination of Disopyramide and Timolol.	Essential hypertension [BA00]	[50]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Ethacrynic acid.	Essential hypertension [BA00]	[22]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Bendroflumethiazide.	Essential hypertension [BA00]	[22]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Benzthiazide.	Essential hypertension [BA00]	[22]
Nadolol	DMW6GVL	Major	Increased risk of bradycardia by the combination of Disopyramide and Nadolol.	Essential hypertension [BA00]	[50]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Disopyramide caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[51]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Solifenacin.	Functional bladder disorder [GC50]	[16]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Tolterodine.	Functional bladder disorder [GC50]	[23]
Darifenacin	DMWXLYZ	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Darifenacin.	Functional bladder disorder [GC50]	[23]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Disopyramide caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[16]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pentamidine.	Fungal infection [1F29-1F2F]	[16]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Disopyramide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[52]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Disopyramide caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[53]
Amphotericin B	DMTAJQE	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Amphotericin B.	Fungal infection [1F29-1F2F]	[22]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Propantheline.	Gastric ulcer [DA60]	[23]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[16]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[16]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Acetazolamide.	Glaucoma [9C61]	[22]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Disopyramide when combined with Isoflurophate.	Glaucoma [9C61]	[37]
Carteolol	DMFMDOB	Major	Increased risk of bradycardia by the combination of Disopyramide and Carteolol.	Glaucoma [9C61]	[50]
Metipranolol	DMJMVKI	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Metipranolol.	Glaucoma [9C61]	[50]
Levobetaxolol	DMSREPX	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Levobetaxolol.	Glaucoma [9C61]	[50]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Levobunolol.	Glaucoma [9C61]	[50]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Disopyramide when combined with Pilocarpine.	Glaucoma [9C61]	[19]
Carvedilol	DMHTEAO	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Carvedilol.	Heart failure [BD10-BD1Z]	[50]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Chlorothiazide.	Heart failure [BD10-BD1Z]	[22]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Furosemide.	Heart failure [BD10-BD1Z]	[22]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Bumetanide.	Heart failure [BD10-BD1Z]	[22]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[22]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Disopyramide caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[54]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Disopyramide caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[55]
Telaprevir	DMMRV29	Major	Decreased metabolism of Disopyramide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[22]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Disopyramide caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[56]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Disopyramide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[57]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Disopyramide caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Disopyramide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Disopyramide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Disopyramide caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Disopyramide caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Disopyramide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Disopyramide caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Ritonavir	DMU764S	Major	Decreased metabolism of Disopyramide caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Acebutolol	DM0TI4U	Major	Additive hypotensive effects by the combination of Disopyramide and Acebutolol.	Hypertension [BA00-BA04]	[50]
Bisoprolol	DM3UZ95	Major	Increased risk of hypoglycemia by the combination of Disopyramide and Bisoprolol.	Hypertension [BA00-BA04]	[50]
Penbutolol	DM4ES8F	Major	Increased risk of hypoglycemia by the combination of Disopyramide and Penbutolol.	Hypertension [BA00-BA04]	[50]
Nebivolol	DM7F1PA	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Nebivolol.	Hypertension [BA00-BA04]	[50]
Diltiazem	DMAI7ZV	Moderate	Decreased metabolism of Disopyramide caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[62]
Pindolol	DMD2NV7	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pindolol.	Hypertension [BA00-BA04]	[50]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Indapamide.	Hypertension [BA00-BA04]	[22]
Labetalol	DMK8U72	Major	Additive hypotensive effects by the combination of Disopyramide and Labetalol.	Hypertension [BA00-BA04]	[50]
Atenolol	DMNKG1Z	Major	Increased risk of bradycardia by the combination of Disopyramide and Atenolol.	Hypertension [BA00-BA04]	[50]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[22]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Disopyramide and Potassium chloride.	Hypo-kalaemia [5C77]	[63]
Conivaptan	DM1V329	Major	Decreased metabolism of Disopyramide caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[64]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[22]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[23]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Amantadine.	Influenza [1E30-1E32]	[65]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Disopyramide caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Pentobarbital	DMFNH7L	Moderate	Increased metabolism of Disopyramide caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Propiomazine.	Insomnia [7A00-7A0Z]	[23]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Disopyramide and ITI-007.	Insomnia [7A00-7A0Z]	[23]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[66]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[16]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Clidinium.	Irritable bowel syndrome [DD91]	[23]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Dicyclomine.	Irritable bowel syndrome [DD91]	[23]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Disopyramide when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[25]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Crizotinib.	Lung cancer [2C25]	[16]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Disopyramide caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[67]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ceritinib.	Lung cancer [2C25]	[16]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Disopyramide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Osimertinib.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lumefantrine.	Malaria [1F40-1F45]	[15]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Halofantrine.	Malaria [1F40-1F45]	[69]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Chloroquine.	Malaria [1F40-1F45]	[16]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Hydroxychloroquine.	Malaria [1F40-1F45]	[16]
Quinine	DMSWYF5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Quinine.	Malaria [1F40-1F45]	[16]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Primaquine.	Malaria [1F40-1F45]	[16]
Mefloquine	DMWT905	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Mefloquine.	Malaria [1F40-1F45]	[16]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Idelalisib	DM602WT	Major	Decreased metabolism of Disopyramide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[28]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Disopyramide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[70]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[71]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Disopyramide caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[72]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Vemurafenib.	Melanoma [2C30]	[16]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Disopyramide and LGX818.	Melanoma [2C30]	[16]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Disopyramide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[22]
Propranolol	DM79NTF	Major	Increased risk of bradycardia by the combination of Disopyramide and Propranolol.	Migraine [8A80]	[50]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Disopyramide caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[73]
Doxylamine	DMKOXFE	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Doxylamine.	Morning sickness disorder [SC00]	[23]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Panobinostat.	Multiple myeloma [2A83]	[16]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Siponimod.	Multiple sclerosis [8A40]	[15]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ozanimod.	Multiple sclerosis [8A40]	[16]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Disopyramide when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[74]
Pyridostigmine	DM8HO1L	Moderate	Antagonize the effect of Disopyramide when combined with Pyridostigmine.	Myasthenia gravis [8C6Y]	[74]
Edrophonium	DMCRQHB	Moderate	Antagonize the effect of Disopyramide when combined with Edrophonium.	Myasthenia gravis [8C6Y]	[74]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Disopyramide when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[74]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Disopyramide caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[56]
Bexarotene	DMOBIKY	Moderate	Increased metabolism of Disopyramide caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[22]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Romidepsin.	Mycosis fungoides [2B01]	[16]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Disopyramide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Disopyramide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[75]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[16]
Modafinil	DMYILBE	Minor	Increased metabolism of Disopyramide caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[76]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Phenindamine.	Nasopharyngitis [CA00]	[23]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Droperidol.	Nausea/vomiting [MD90]	[16]
Dimenhydrinate	DM264B3	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Dimenhydrinate.	Nausea/vomiting [MD90]	[15]
Prochlorperazine	DM53SRA	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Prochlorperazine.	Nausea/vomiting [MD90]	[16]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Promethazine.	Nausea/vomiting [MD90]	[16]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Cyclizine.	Nausea/vomiting [MD90]	[23]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Palonosetron.	Nausea/vomiting [MD90]	[16]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Disopyramide when combined with Metoclopramide.	Nausea/vomiting [MD90]	[77]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Granisetron.	Nausea/vomiting [MD90]	[16]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Dolasetron.	Nausea/vomiting [MD90]	[16]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ondansetron.	Nausea/vomiting [MD90]	[16]
Thiethylperazine	DMU3IET	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Thiethylperazine.	Nausea/vomiting [MD90]	[23]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Entrectinib.	Non-small cell lung cancer [2C25]	[16]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Chlorthalidone.	Oedema [MG29]	[22]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Metolazone.	Oedema [MG29]	[22]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Polythiazide.	Oedema [MG29]	[22]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[22]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lofexidine.	Opioid use disorder [6C43]	[16]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Rucaparib.	Ovarian cancer [2C73]	[16]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Dextropropoxyphene.	Pain [MG30-MG3Z]	[16]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Flavoxate.	Pain [MG30-MG3Z]	[23]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Buprenorphine.	Pain [MG30-MG3Z]	[16]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Triclabendazole.	Parasitic worm infestation [1F90]	[16]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Biperiden.	Parkinsonism [8A00]	[23]
Procyclidine	DMHFJDT	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Procyclidine.	Parkinsonism [8A00]	[23]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pimavanserin.	Parkinsonism [8A00]	[16]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Orphenadrine.	Parkinsonism [8A00]	[23]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Apomorphine.	Parkinsonism [8A00]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Disopyramide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[78]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Methylscopolamine.	Peptic ulcer [DA61]	[23]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Disopyramide and Famotidine.	Peptic ulcer [DA61]	[15]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[79]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lefamulin.	Pneumonia [CA40]	[80]
Prednisone	DM2HG4X	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Prednisone.	Postoperative inflammation [1A00-CA43]	[22]
Betamethasone	DMAHJEF	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Betamethasone.	Postoperative inflammation [1A00-CA43]	[22]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[22]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Disopyramide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[28]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Ritodrine.	Preterm labour/delivery [JB00]	[30]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Disopyramide and ABIRATERONE.	Prostate cancer [2C82]	[16]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Nilutamide.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Enzalutamide.	Prostate cancer [2C82]	[16]
Flutamide	DMK0O7U	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Flutamide.	Prostate cancer [2C82]	[16]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Relugolix.	Prostate cancer [2C82]	[16]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Bicalutamide.	Prostate cancer [2C82]	[16]
Alfuzosin	DMZVMKF	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Alfuzosin.	Prostate hyperplasia [GA90]	[16]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Disopyramide due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[22]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Disopyramide due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[22]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[16]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[16]
Triflupromazine	DMKFQJP	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[16]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Disopyramide caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[81]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Disopyramide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[82]
Sorafenib	DMS8IFC	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Sorafenib.	Renal cell carcinoma [2C90]	[16]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[32]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Disopyramide due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[22]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Disopyramide due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[22]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Cyproheptadine.	Rheumatoid arthritis [FA20]	[23]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Disopyramide due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[22]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Disopyramide due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[22]
Dexamethasone	DMMWZET	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Dexamethasone.	Rheumatoid arthritis [FA20]	[22]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Disopyramide due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[22]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Quetiapine.	Schizophrenia [6A20]	[16]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Mesoridazine.	Schizophrenia [6A20]	[16]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Thioridazine.	Schizophrenia [6A20]	[16]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Aripiprazole.	Schizophrenia [6A20]	[23]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Paliperidone.	Schizophrenia [6A20]	[16]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Loxapine.	Schizophrenia [6A20]	[23]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Haloperidol.	Schizophrenia [6A20]	[16]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Perphenazine.	Schizophrenia [6A20]	[16]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Molindone.	Schizophrenia [6A20]	[23]
Chlorpromazine	DMBGZI3	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Chlorpromazine.	Schizophrenia [6A20]	[16]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Thiothixene.	Schizophrenia [6A20]	[23]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Clozapine.	Schizophrenia [6A20]	[16]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Trifluoperazine.	Schizophrenia [6A20]	[16]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Risperidone.	Schizophrenia [6A20]	[16]
Olanzapine	DMPFN6Y	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Olanzapine.	Schizophrenia [6A20]	[23]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Amisulpride.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Asenapine.	Schizophrenia [6A20]	[16]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pimozide.	Schizophrenia [6A20]	[22]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[83]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Disopyramide caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[22]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Disopyramide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Methylprednisolone	DM4BDON	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[22]
Armodafinil	DMGB035	Minor	Increased metabolism of Disopyramide caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[76]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Disopyramide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[16]
Epirubicin	DMPDW6T	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Cisplatin	DMRHGI9	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[84]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Pitolisant.	Somnolence [MG42]	[16]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[16]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[85]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Disopyramide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[86]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Lenvatinib.	Thyroid cancer [2D10]	[16]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Cabozantinib.	Thyroid cancer [2D10]	[16]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Papaverine.	Tonus and reflex abnormality [MB47]	[87]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Tizanidine.	Tonus and reflex abnormality [MB47]	[16]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Disopyramide and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[82]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Tacrolimus.	Transplant rejection [NE84]	[16]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[20]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[20]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[20]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Disopyramide and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[20]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Atropine.	Unspecific substance harmful effect [NE6Z]	[23]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[16]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[23]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[23]
Triamcinolone	DM98IXF	Moderate	Increased risk of ventricular arrhythmias by the combination of Disopyramide and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[22]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[23]
Clemastine	DMBZWQL	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Clemastine.	Vasomotor/allergic rhinitis [CA08]	[23]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[23]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Disopyramide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[23]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[23]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[23]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Disopyramide and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[23]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Food blue 1 aluminum lake	E00512	11979396	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbitan monolaurate	E00508	11046239	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Ethyl cellulose	E00699	Not Available	Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
Shellac	E00695	Not Available	Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Disopyramide 100 mg capsule	100 mg	Oral Capsule	Oral
Disopyramide 150 mg capsule	150 mg	Oral Capsule	Oral
Disopyramide 150 mg capsule	150 mg	12 HR Extended Release Oral Capsule	Oral
Disopyramide Phosphate eq 100mg base capsule	eq 100mg base	Capsule	Oral
Disopyramide Phosphate eq 150mg base capsule	eq 150mg base	Capsule	Oral
Disopyramide 100 mg capsule	100 mg	12 HR Extended Release Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Disopyramide FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7167).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [8] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [9] Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
• [10] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [11] Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
• [12] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [13] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [14] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Canadian Pharmacists Association.
• [17] Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
• [18] James MA, Papouchado M, Vann Jones J "Combined therapy with disopyramide and amiodarone: a report of 11 cases." Int J Cardiol 13 (1986): 248-52. [PMID: 3793283]
• [19] Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
• [20] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [21] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [22] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [23] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [24] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [25] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [26] Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
• [27] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
• [28] Product Information. Norpace (disopyramide). Searle, Skokie, IL.
• [29] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [31] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
• [32] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [33] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
• [34] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [35] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [36] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [37] Multum Information Services, Inc. Expert Review Panel.
• [38] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
• [39] Kapil RP, Axelson JE, Mansfield IL, et al. "Disopyramide pharmacokinetics and metabolism: effect of inducers." Br J Clin Pharmacol 24 (1987): 781-91. [PMID: 3440098]
• [40] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [41] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [42] Ellrodt G, Singh BN "Adverse effects of disopyramide (norpace): toxic interactions with other antiarrhythmic agents." Heart Lung 9 (1980): 469-74. [PMID: 6901519]
• [43] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [44] Olsen H, Bredesen JE, Lunde PK "Effect of ethanol intake on disopyramide elimination by healthy volunteers." Eur J Clin Pharmacol 25 (1983): 103-5. [PMID: 6617710]
• [45] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [46] Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
• [47] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [48] Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Aitio ML, Mansury L, Tala E, et al "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
• [50] Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
• [51] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [52] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [53] Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ. (1992):.
• [54] Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
• [55] Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
• [56] Aitio ML, Mansury L, Tala E, Haataja M, Aitio A "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
• [57] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [58] Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
• [59] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [60] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [61] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [62] Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
• [63] Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
• [64] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [65] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [66] Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
• [67] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [68] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [69] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [70] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [71] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [72] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [73] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [74] Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
• [75] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [76] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [77] Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
• [78] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [79] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [80] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [81] Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
• [82] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [83] Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
• [84] Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [85] Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
• [86] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [87] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]